{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:28:53Z","timestamp":1787009333010,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"W1","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","award":["15414"],"award-info":[{"award-number":["15414"]}],"id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["361454"],"award-info":[{"award-number":["361454"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","award":["#399980"],"award-info":[{"award-number":["#399980"]}],"id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-combination data portals have recently been introduced to mine huge amounts of pharmacological data with the aim of improving current chemotherapy strategies. However, these portals have only been investigated for isolated datasets, and molecular profiles of cancer cell lines are lacking. Here we developed a cloud-based pharmacogenomics portal called SYNERGxDB (http:\/\/SYNERGxDB.ca\/) that integrates multiple high-throughput drug-combination studies with molecular and pharmacological profiles of a large panel of cancer cell lines. This portal enables the identification of synergistic drug combinations through harmonization and unified computational analysis. We integrated nine of the largest drug combination datasets from both academic groups and pharmaceutical companies, resulting in 22 507 unique drug combinations (1977 unique compounds) screened against 151 cancer cell lines. This data compendium includes metabolomics, gene expression, copy number and mutation profiles of the cancer cell lines. In addition, SYNERGxDB provides analytical tools to discover effective therapeutic combinations and predictive biomarkers across cancer, including specific types. Combining molecular and pharmacological profiles, we systematically explored the large space of univariate predictors of drug synergism. SYNERGxDB constitutes a comprehensive resource that opens new avenues of research for exploring the mechanism of action for drug synergy with the potential of identifying new treatment strategies for cancer patients.<\/jats:p>","DOI":"10.1093\/nar\/gkaa421","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T15:09:27Z","timestamp":1588777767000},"page":"W494-W501","source":"Crossref","is-referenced-by-count":49,"title":["SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology"],"prefix":"10.1093","volume":"48","author":[{"given":"Heewon","family":"Seo","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 0A3, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Tkachuk","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Ho","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mammoliti","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 0A3, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria","family":"Rezaie","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed\u00a0Ali","family":"Madani\u00a0Tonekaboni","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 0A3, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-0079","authenticated-orcid":false,"given":"Benjamin","family":"Haibe-Kains","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 0A3, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada"},{"name":"Department of Computer Science, University of Toronto, Toronto, Ontario M5T 3A1, Canada"},{"name":"Ontario Institute for Cancer Research, Toronto, Ontario, Canada"},{"name":"Vector Institute for Artificial Intelligence, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"2020062614044624700_B1","doi-asserted-by":"crossref","first-page":"eaaw8412","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"2020062614044624700_B2","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1470-2045(11)70335-7","article-title":"Genetic heterogeneity and cancer drug resistance","volume":"13","author":"Turner","year":"2012","journal-title":"Lancet Oncol."},{"key":"2020062614044624700_B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.2011-S1-30","article-title":"Chemotherapy: updates and new perspectives","volume":"16","author":"Swain","year":"2011","journal-title":"Oncologist"},{"key":"2020062614044624700_B4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le\u00a0Tourneau","year":"2015","journal-title":"Lancet Oncol."},{"key":"2020062614044624700_B5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40169-018-0185-6","article-title":"Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs","volume":"7","author":"Maeda","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"2020062614044624700_B6","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat\u00a0Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"2020062614044624700_B7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2020062614044624700_B8","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1200\/JCO.2011.40.5241","article-title":"Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer","volume":"31","author":"Guan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2020062614044624700_B9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.biomaterials.2015.02.004","article-title":"Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response","volume":"52","author":"Jiang","year":"2015","journal-title":"Biomaterials"},{"key":"2020062614044624700_B10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bib\/bbw104","article-title":"Predictive approaches for drug combination discovery in cancer","volume":"19","author":"Madani\u00a0Tonekaboni","year":"2018","journal-title":"Brief. Bioinform."},{"key":"2020062614044624700_B11","doi-asserted-by":"crossref","first-page":"W43","DOI":"10.1093\/nar\/gkz337","article-title":"DrugComb: an integrative cancer drug combination data portal","volume":"47","author":"Zagidullin","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2020062614044624700_B12","first-page":"D871","article-title":"DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy","volume":"48","author":"Liu","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2020062614044624700_B13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","article-title":"The cellosaurus, a cell-line knowledge resource","volume":"29","author":"Bairoch","year":"2018","journal-title":"J. Biomol. Tech."},{"key":"2020062614044624700_B14","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2020062614044624700_B15","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"2020062614044624700_B16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","article-title":"Prediction of drug combination effects with a minimal set of experiments","volume":"1","author":"Ianevski","year":"2019","journal-title":"Nat. Mach. Intel."},{"key":"2020062614044624700_B17","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1158\/1535-7163.MCT-16-0794","article-title":"Combinatorial screening of pancreatic adenocarcinoma reveals sensitivity to drug combinations including bromodomain inhibitor plus neddylation inhibitor","volume":"16","author":"Langdon","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"2020062614044624700_B18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cels.2017.05.002","article-title":"Systematic quantification of population cell death kinetics in mammalian cells","volume":"4","author":"Forcina","year":"2017","journal-title":"Cell Syst."},{"key":"2020062614044624700_B19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nchembio.2382","article-title":"A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor","volume":"13","author":"Licciardello","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"2020062614044624700_B20","doi-asserted-by":"crossref","first-page":"e0140310","DOI":"10.1371\/journal.pone.0140310","article-title":"Landscape of targeted Anti-cancer drug synergies in melanoma identifies a novel BRAF-VEGFR\/PDGFR combination treatment","volume":"10","author":"Friedman","year":"2015","journal-title":"PLoS One"},{"key":"2020062614044624700_B21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/0008-5472.CAN-16-1901","article-title":"Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer","volume":"77","author":"Wali","year":"2017","journal-title":"Cancer Res."},{"key":"2020062614044624700_B22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-15-0843","article-title":"An unbiased oncology compound screen to identify novel combination strategies","volume":"15","author":"O\u2019Neil","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"2020062614044624700_B23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cels.2019.05.009","article-title":"VISAGE reveals a targetable mitotic spindle vulnerability in cancer cells","volume":"9","author":"Patterson","year":"2019","journal-title":"Cell Syst."},{"key":"2020062614044624700_B24","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/0008-5472.CAN-17-0489","article-title":"The national cancer institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity","volume":"77","author":"Holbeck","year":"2017","journal-title":"Cancer Res."},{"key":"2020062614044624700_B25","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/bioinformatics\/btv723","article-title":"PharmacoGx: an R package for analysis of large pharmacogenomic datasets","volume":"32","author":"Smirnov","year":"2016","journal-title":"Bioinformatics"},{"key":"2020062614044624700_B26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2020062614044624700_B27","doi-asserted-by":"crossref","first-page":"D923","DOI":"10.1093\/nar\/gky872","article-title":"Cell Model Passports\u2014a hub for clinical, genetic and functional datasets of preclinical cancer models","volume":"47","author":"van\u00a0der\u00a0Meer","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2020062614044624700_B28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2020062614044624700_B29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2020062614044624700_B30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"2020062614044624700_B31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01952257","article-title":"\u00dcber Kombinationswirkungen","volume":"114","author":"Loewe","year":"1926","journal-title":"Naunyn-Schmiedebergs Archiv. Exp. Pathol. Pharmakol."},{"key":"2020062614044624700_B32","first-page":"93","article-title":"What is synergy","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol. Rev."},{"key":"2020062614044624700_B33","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"2020062614044624700_B34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat. Med."},{"key":"2020062614044624700_B35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2020062614044624700_B36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","article-title":"Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance","volume":"164","author":"Marcotte","year":"2016","journal-title":"Cell"},{"key":"2020062614044624700_B37","doi-asserted-by":"crossref","first-page":"i228","DOI":"10.1093\/bioinformatics\/btu278","article-title":"DrugComboRanker: drug combination discovery based on target network analysis","volume":"30","author":"Huang","year":"2014","journal-title":"Bioinformatics"},{"key":"2020062614044624700_B38","doi-asserted-by":"crossref","first-page":"8481","DOI":"10.1038\/ncomms9481","article-title":"Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer","volume":"6","author":"Sun","year":"2015","journal-title":"Nat. Commun."},{"key":"2020062614044624700_B39","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/0008-5472.CAN-17-0096","article-title":"Integrative cancer pharmacogenomics to infer large-scale drug taxonomy","volume":"77","author":"El-Hachem","year":"2017","journal-title":"Cancer Res."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/48\/W1\/W494\/33433265\/gkaa421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/48\/W1\/W494\/33433265\/gkaa421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T02:34:50Z","timestamp":1593225290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/48\/W1\/W494\/5842189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":39,"journal-issue":{"issue":"W1","published-online":{"date-parts":[[2020,5,22]]},"published-print":{"date-parts":[[2020,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaa421","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,2]]},"published":{"date-parts":[[2020,5,22]]}}}